ArticleJournal of cancer science and clinical therapeutics2026
Critical Insights into Parathyroid Cancer.
Article in Journal of cancer science and clinical therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Parathyroid carcinoma (PC) is a rare endocrine malignancy accounting for less than 1% of primary hyperparathyroidism cases. It carries significant morbidity due to severe hypercalcemia and a high rate of recurrence post-resection. This literature review synthesizes current evidence on the diagnostic challenges, surgical management, and outcomes associated with parathyroid carcinoma. Diagnosis of parathyroid carcinoma remains difficult due to a large overlap with parathyroid adenoma in clinical presentation, laboratory findings, and imaging characteristics. However, markedly elevated serum calcium and parathyroid hormone levels, palpable neck mass, and evidence of local invasion may raise suspicion for malignancy. Definitive diagnosis relies on histopathologic features such as capsular, vascular, or perineural invasion. Also, many immunohistochemical markers are currently under review, including mutation of the CDC73 gene, loss of parafibromin, and elevated Ki-67, which support the diagnosis. Complete
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.